Dr. Stefan Irion is the Chief Scientific Officer of BlueRock Therapeutics and Dr. Viviane Tabar is the Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center.  In this special episode, recorded in front of a live audience in New York, they talk about their work on BlueRock's clinical trial for bemdaneprocel — a stem cell-derived investigational cell therapy for Parkinson's disease. They also discuss what's next for cell therapy and diversity in science and in patients.